Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Evidence for the Involvement of Toll-Like Receptor 4 (TLR4)-Mediated Apoptosis in Gynecological Cancers

Version 1 : Received: 19 December 2016 / Approved: 20 December 2016 / Online: 20 December 2016 (11:12:07 CET)

How to cite: Won, J.; Lee, Y.; Chang, K.; Hong, Y. Evidence for the Involvement of Toll-Like Receptor 4 (TLR4)-Mediated Apoptosis in Gynecological Cancers. Preprints 2016, 2016120107. https://doi.org/10.20944/preprints201612.0107.v1 Won, J.; Lee, Y.; Chang, K.; Hong, Y. Evidence for the Involvement of Toll-Like Receptor 4 (TLR4)-Mediated Apoptosis in Gynecological Cancers. Preprints 2016, 2016120107. https://doi.org/10.20944/preprints201612.0107.v1

Abstract

Toll-like receptor 4 (TLR4) is a member of the TLR family. Members of the TLR family play an important role in innate immune responses and are induced by recognition of pathogen-associated molecular patterns. They are also involved in cell proliferation and apoptosis in cancer. We investigated the role of TLR4 in apoptotic cell death in gynecological cancer cells; gynecological cancer is associated with infertility and spontaneous abortion. To examine the effect of TLR4 activation on apoptotic signaling in cancer cells, cultured primary cancer cells were treated with the TLR4 agonist lipopolysaccharide (LPS). The morphology of cancer cells was compared with normal myometrial cells. Enhanced growth rate and loss of contact inhibition with cellular overlap was observed in the cancer cells. The molecular mechanism analysis revealed differential expression of tumor suppressor genes in LPS-treated cancer cells. The expression of apoptosis-related caspase-3 was increased significantly in cancer cells with TLR4 activation after exposure to LPS. Taken together, these results suggest the pro-apoptotic activity of TLR4 as a potential therapeutic target for the treatment of gynecological cancers.

Keywords

apoptosis; gynecologic cancer; lipopolysaccharide; proliferation; Toll-like receptor

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.